Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.  The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients.

"Patients with Alzheimer's disease have a number of symptomatic therapies available to them. However, the effects of the available medications are modest. Even if significant progress is made in slowing disease progression, more effective therapies that sustainably improve the cognition of the patients are clearly needed," said Kees Been, EnVivo president and CEO. "There is growing consensus that alpha-7 nicotinic agonists can potentially improve the cognitive function in Alzheimer's disease patients as evidenced by the number of large pharmaceutical companies advancing similar drugs through development. The potential upside for patients is considerable and we look forward to completing our Alzheimer's disease study by the middle of next year."

The Phase IIb study will enroll mild to moderate Alzheimer's disease patients who will be randomized to three separate doses of EVP-6124 or placebo over six months. Efficacy will primarily be determined by the ADAS-Cog scale, a commonly used and accepted measure of cognition in patients with Alzheimer's disease. Secondary assessments will include other cognitive and clinical measures. EVP-6124 also is being tested in patients with schizophrenia in a separate Phase IIb study that started in late 2009
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  The Broad Institute today announced ... Ted Stanley aimed at galvanizing scientific ... based on molecular understanding to hundreds of millions ... The Stanley commitment – the largest ever in ... research in general – will support research by ...
(Date:7/22/2014)... , 22. Juli 2014 Qforma, ein ... die Ernennung von Marcus Bergler zum General Manager ... hat die europäischen kommerziellen Aktivitäten von Qforma bereits ... sich Qforma anschloss, war er in Positionen als ... als Vertriebsteam-Leiter Deutschland bei IMS Health und als ...
(Date:7/21/2014)... Lawrence Livermore National Laboratory ... Las Positas College (LPC) recently established a 24-month ... training for veterans, officials recently announced. , The ... is designed to help veterans develop the ... and establishes a pipeline of qualified candidates for ...
(Date:7/21/2014)... EUGENE, Ore. (July 21, 2014) The yield ... of Oregon have developed a low-energy, solution-based mineral substitution ... that could find use in electronics and alternative energy ... on the cover of the July 21 issue of ... most citations of research in the inorganic and nuclear ...
Breaking Biology Technology:$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Oregon chemists eye improved thin films with metal substitution 2
... Mass., March 17 The pro bono healthcare ... ), has announced that its newly instituted Safe ... Lutheran Health System of La Crosse, Wisconsin. The ... outstanding accomplishments in safe patient handling, safe lifting, ...
... Pharmaceuticals Inc., a specialty pharmaceutical company, announces the ... Vice President of the Ferring International PharmaScience Center ... Pharmaceuticals Inc. Dr. Korner was formerly Vice ... and Gastroenterology therapeutic areas, as well as Product ...
... 19, 2009 at 11:00 AM ET LIVINGSTON, N.J., ... Inc. (OTC Bulletin Board: MLSS), the recognized leader in ... file its 2008 year-end results for the 12 months ... Exchange Commission on Tuesday, March 17, 2009. Having ...
Cached Biology Technology:Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 2Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 3Dr. Paul Korner Promoted to Senior Vice President of Ferring International PharmaScience Center U.S. 2Milestone Scientific to Report 2008 Year-End Results on Tuesday, March 17, 2009 2Milestone Scientific to Report 2008 Year-End Results on Tuesday, March 17, 2009 3
(Date:7/22/2014)... most kids will hear that drinking milk helps make their bones ... these messages foster the idea that if something is good for ... in the Journal of Consumer Research , when children hear ... it. , "We predicted that when food is presented to children ... goal such as learning how to read or count, they would ...
(Date:7/22/2014)... MSN, APRN, PMHCNS-BC, CNE, Assistant Professor of Clinical ... School of Nursing, contributed samples used in a ... with schizophrenia and also suggesting a possible link ... Biological insights from 108 schizophrenia-associated genetic loci, was ... , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
(Date:7/22/2014)... side of meerkats which sees them prevent their daughters ... a new study. , Research into the desert creatures ... many adult helpers shows that the alpha female can ... The study shows how this way of life, also found ... effective despite its sinister side. , Dominant meerkats control ...
Breaking Biology News(10 mins):LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... Many of society,s most challenging health issues, including obesity, ... University of Missouri researchers are examining the multiple facets ... from medicine and research to policy and law to ... in the Mizzou Advantage (During a three-year process, MU ...
... of the Key West, Fla., population over 1,000 people ... 2009, according to a report from the Centers for Disease ... After three initial locally acquired cases of dengue were ... Department of Health conducted a study to estimate the potential ...
... Detecting oral cancer in its earliest stages can save ... early detection has been difficult. Case Western Reserve ... human beta defensin-3 (hBD-3), which may serve as an early ... and associated with the early stages of oral cancer. ...
Cached Biology News:Food for our future -- it's more than what's for dinner 2Food for our future -- it's more than what's for dinner 3Report suggests nearly 5 percent exposed to dengue virus in Key West 2CWRU dental researchers discover human beta defensins-3 ignite in oral cancer growth 2